Factors predicting chemotherapy induced peripheral neuropathy in breast cancer patients receiving neurotoxic chemotherapy
Keywords:
Neurotoxic chemotherapy, chemotherapy induced peripheral neuropathy, predictor, breast cancerAbstract
Background: Cancer is a major cause of death worldwide. Chemotherapy is an effective treatment that is widely used to increase the numbers of cancer survivors. However, it often causes side effects such as nausea, vomiting, and lack of appetite. Chemotherapy induced peripheral neuropathy (CIPN) is one of the most serious side effect leading to fatal outcomes in these patients.
Objectives: To examine the influence of patient characteristics (body mass index: BMI, age, and physical activity), clinical characteristic (anemia) and treatment related factors (dosage of neurotoxic chemotherapy) on CIPN in cancer patients receiving neurotoxic chemotherapy.
Methods: One hundred and twenty Thai patients with breast cancer were recruited using the convenience sampling at a Chemotherapy and Blood Transfusion Unit at a university hospital in Bangkok. Research instruments included a personal information form, body mass index (BMI) record, physical activity questionnaire, and CIPN 20 questionnaire. Hemoglobin level was obtained from the laboratory records. The dosage of neurotoxic chemotherapy was obtained from each patients’ medical record form. Data were analysed by using descriptive statistics, spearman’s rho, and logistic regression analysis.
Results: The results showed that the patient characteristics (BMI, age, and physical activity), clinical characteristic (anemia), and treatment related factors (dosage of neurotoxic chemotherapy) could predict CIPN, but only physical activity and dosage of neurotoxic chemotherapy were most significant predictors of CIPN. Physical activity (OR = 0.99, 95%CI = 0.98 - 1.00, P = 0.04) and dosage of neurotoxic chemotherapy (OR = 1.01, 95%CI = 1.00 - 1.02, P = 0.00) were significant predictors of CIPN.
Conclusion: The findings recommend that health care providers should prepare to improve physical activity of breast cancer patients before receiving neurotoxic chemotherapy and closely monitor the patient receiving high dose of neurotoxic chemotherapy in order to prevent and reduce CIPN.
Downloads
References
Virani S, Bilheem S, Chansaard W, Chitapanarux I, Daoprasert K, Khuanchana S, et al. National and subnational population-based incidence of cancer in Thailand: Assessing cancers with the highest burdens. Cancers (Basel) 2017;9:pii:E108. https://doi.org/10.3390/cancers9080108
Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (cipn): A systematic review. Clin Nutr 2013;32:888-93.
https://doi.org/10.1016/j.clnu.2013.04.007
Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based profiles registry. Gynecol Oncol 2014;135:510-7.
https://doi.org/10.1016/j.ygyno.2014.09.016
Kumar SP, Jamwal NR. Assessment and treatment of chemotherapy-induced peripheral neuropathy: Aphysical therapy perspective. J Cancer Biol Therap 2015;1:12-28. https://doi.org/10.18314/gjct.v1i1.28
Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 2016;159:327-33. https://doi.org/10.1007/s10549-016-3939-0
Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, et al. BMI, lifestyle factors and taxaneinduced neuropathy in breast cancer patients: The pathways study. J Natl Cancer Inst 2017;109:pii:djw206. https://doi.org/10.1093/jnci/djw206
Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Supportive Care in Cancer 2017;25:2241-8. https://doi.org/10.1007/s00520-017-3631-x
Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 2013;18:132-8. https://doi.org/10.1007/s10147-011-0352-x
Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 2016;34:3014-22. https://doi.org/10.1200/JCO.2015.66.2346
Cox-Martin E, Trahan LH, Cox MG, Dougherty PM, Lai EA, Novy DM. Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer 2017;25:1873-9. https://doi.org/10.1007/s00520-017-3571-5
Candelario N, Wongrakpanich S, Morginstin MS. Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes. J Clin Oncol 2015;33(28 Suppl):90.
https://doi.org/10.1200/jco.2015.33.28_suppl.90
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer 2014;22:2261-9.
https://doi.org/10.1007/s00520-014-2255-7
Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol 2014;25:493-9. https://doi.org/10.1093/annonc/mdt568
Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant folfox iv. Support Care Cancer 2013;21:1313-9. https://doi.org/10.1007/s00520-012-1667-5
Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer Prev 2015;16:7603-6. https://doi.org/10.7314/APJCP.2015.16.17.7603
Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev 2014;40:872-82. https://doi.org/10.1016/j.ctrv.2014.04.004
Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci 1997;19:14-27. https://doi.org/10.1097/00012272-199703000-00003
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91.
https://doi.org/10.3758/BF03193146
Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, et al. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 2002;50:530-4.
https://doi.org/10.1046/j.1532-5415.2002.50122.x
Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, et al. 2011 compendium of physical activities: A second update of codes and met values. Med Sci Sports Exerc 2011;43:1575-81. https://doi.org/10.1249/MSS.0b013e31821ece12
National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Cancer-and chemotherapy-induced anemia. Version 3. 2014. Plymouth Meeting, PA: NCCN;2014.
Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (cipn) as measured by the eortc qlq-cipn20 instrument, no6ca. Support Care Cancer 2012;20:625-32.
https://doi.org/10.1007/s00520-011-1141-9
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an eortc quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The qlq-cipn20. Eur J Cancer 2005;41:1135-9. https://doi.org/10.1016/j.ejca.2005.02.012
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014;155:2461-70. https://doi.org/10.1016/j.pain.2014.09.020
Panyainkaew P. Chemotherapy induced peripheral neuropathy, managements, and outcomes as perceived by cancer patients [thesis]. Bangkok: Mahidol University; 2016. [in Thai]
Simon NB, Danso MA, Alberico TA, Basch E, Bennett AV. The prevalence and pattern of chemotherapyinduced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res 2017;26,2763-72. https://doi.org/10.1007/s11136-017-1635-0
Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 2006;14:223-9. https://doi.org/10.1007/s00520-005-0868-6
Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of chemotherapyinduced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 2013;9:e234-40. https://doi.org/10.1200/JOP.2012.000863
Tsurutani J, Sakata Y, Matsuoka T. Chemotherapyinduced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study. Breast Cancer 2019;26:235-43. https://doi.org/10.1007/s12282-018-0919-8
Wonders KY, Drury DG. Current exercise behaviors of breast cancer patients diagnosed with chemotherapy-induced peripheral neuropathy. J Integr Oncol 2012;1:1-4.
https://doi.org/10.4172/2329-6771.1000103
Stevinson C, Steed H, Faught W, Tonkin K, Vallance JK, Ladha AB, et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer 2009;19:73-8. https://doi.org/10.1111/IGC.0b013e31819902ec
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chulalongkorn Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
